CorMedix Inc.  

(Public, NYSEMKT:CRMD)   Watch this stock  
Find more results for CRMD
4.18
-0.08 (-1.88%)
Apr 29 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 4.11 - 4.50
52 week 1.15 - 8.02
Open 4.26
Vol / Avg. 220,307.00/329,566.00
Mkt cap 143.43M
P/E     -
Div/yield     -
EPS -0.61
Shares 36.12M
Beta 0.58
Inst. own 23%
May 5, 2016
Q1 2016 CorMedix Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 16, 2016
CorMedix Inc at ROTH Conference
Mar 16, 2016
Q4 2015 CorMedix Inc Earnings Release
Mar 16, 2016
Q4 2015 CorMedix Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -16846.54% -8655.37%
Operating margin -10064.88% -7925.56%
EBITD margin - -7918.38%
Return on average assets -40.59% -86.20%
Return on average equity -44.05% -96.80%
Employees 9 -
CDP Score - -

Address

1430 US Highway 206 Ste 200
BEDMINSTER, NJ 07921-4602
United States - Map
+1-908-5179500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CorMedix Inc. (CorMedix) is a pharmaceutical company that in-licenses, develops and commercializes prophylactic and therapeutic products for the treatment of infectious diseases in cardiac, renal and oncology patients. The Company has in-licensed all of the products in its pipeline. The Company's primary product is Neutrolin, a catheter lock solution, which is used the treatment of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. It has the worldwide rights to develop and commercialize product candidates, CRMD003 (Neutrolin) and CRMD004. The Company manufactures CRMD003 (Neutrolin) through Navinta LLC, a United States-based active pharmaceutical ingredient (API) developer. The CRMD004 is the gel formulation of Neutrolin, which is in the pre-clinical stage of development.

Officers and directors

Cora M. Tellez Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Randy Milby Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
James Altland Interim Chief Financial Officer
Bio & Compensation  - Reuters
Antony E. Pfaffle M.D. Chief Scientific Officer, Director
Age: 51
Bio & Compensation  - Reuters
Janet M. Dillione Independent Director
Age: 55
Bio & Compensation  - Reuters
Matthew P. Duffy Independent Director
Age: 52
Bio & Compensation  - Reuters
Michael W. George Independent Director
Age: 66
Bio & Compensation  - Reuters
Steven W. Lefkowitz Independent Director
Age: 59
Bio & Compensation  - Reuters
Taunia S. Markvicka Pharm.D. Independent Director
Age: 46
Bio & Compensation  - Reuters